<p>Roche Diagnostics India on Thursday said it has received import licence from the Central Drugs Standard Control Organisation (CDSCO) for its Elecsys Anti-SARS-CoV-2 test kit and is readying to bring it to India.</p>.<p>The import licence has been issued by the drug regulator due to the emergency health situation in public interest, Roche Diagnostics India said in a statement.</p>.<p>"From bringing the globally used tests to the country in record time to establishing the disease control measures by creating COVID-19 diagnostic hubs..., the Indian government and the state governments have been collaborating with various sections of the healthcare system to manage the situation," Roche Diagnostics India MD Shravan Subramanyam said.</p>.<p>Laboratory-based immunodiagnostic testing will complement the existing reverse transcription polymerase chain reaction (RT-PCR) solutions to possibly ascertain coronavirus-related immunity among patients and all those who want to 'go back to work' to bring the health and economic activity back to normalcy, he added.</p>.<p>The test can support priority screening of high-risk groups, such as healthcare workers, delivery service providers, or food supply workers who might already have been exposed and developed an immune response, the statement said.</p>
<p>Roche Diagnostics India on Thursday said it has received import licence from the Central Drugs Standard Control Organisation (CDSCO) for its Elecsys Anti-SARS-CoV-2 test kit and is readying to bring it to India.</p>.<p>The import licence has been issued by the drug regulator due to the emergency health situation in public interest, Roche Diagnostics India said in a statement.</p>.<p>"From bringing the globally used tests to the country in record time to establishing the disease control measures by creating COVID-19 diagnostic hubs..., the Indian government and the state governments have been collaborating with various sections of the healthcare system to manage the situation," Roche Diagnostics India MD Shravan Subramanyam said.</p>.<p>Laboratory-based immunodiagnostic testing will complement the existing reverse transcription polymerase chain reaction (RT-PCR) solutions to possibly ascertain coronavirus-related immunity among patients and all those who want to 'go back to work' to bring the health and economic activity back to normalcy, he added.</p>.<p>The test can support priority screening of high-risk groups, such as healthcare workers, delivery service providers, or food supply workers who might already have been exposed and developed an immune response, the statement said.</p>